Cancer and the Chemical Specialist C
is cell growth gone wild. It is fierce, implacable, elusive. There are over 300 types of cancer; 2 million people a year die of cancer. It has existed in recorded history since 1500 years before Christ. There is no known dependable cure. The most practiced approaches for treatment of cancer are surgery and radiation. But time is not their ally. One of the biggest problems facing cancer therapists today is non-localized cancers, those that spread through the body or affect the blood-making mechanism. The main effort in this area is in developing chemical agents which will hit the cell but not the patient. The chemical industry has started a vast hunt for anti-cancer drugs. It spends millions of dollars a year for basic research and in the analysis of thousands upon thousands of compounds. Chemical specialists have turned up scores of chemicals with temporary effects—but no cures. To date about 20 chemicals are in general clinical use. 100 others in preliminary testing. The complete story of cancer's challenge to the chemical industry was reported recently in the pages of CHEMICAL AND ENGINEERING NEWS. It is one of the many factual and timely C&EN reports which are read weekly by over 100,000 chemical specialists in management, production, research and development. They are the processors, the creators and innovators who directly or indirectly bring new products into being—the research director at Merck, the production manager at Hercules, the vice-president at Esso—the men who initiate, specify and approve every order for chemicals, equipment, instrumentation, and services. C&EN is the newsmagazine of the chemical world, read and believed by over 100,000 chemical specialists every week— twice as many as any other publication. An American Chemical Society Publication. ANCER
Advertising Management: Reinhold Publishing Corporation 430 Park Avenue, New York 22
